Tesamorelin
Tesamorelin is a synthetic growth hormone-releasing factor analog used to reduce excess abdominal visceral fat in HIV-infected adults with lipodystrophy. It is given by subcutaneous injection and is not indicated for general weight loss; notable risks include fluid retention, glucose intolerance, elevated IGF-1, and injection-site reactions.
Overview
Tesamorelin is a synthetic growth hormone-releasing factor analog used to reduce excess abdominal visceral fat in HIV-infected adults with lipodystrophy. It is given by subcutaneous injection and is not indicated for general weight loss; notable risks include fluid retention, glucose intolerance, elevated IGF-1, and injection-site reactions.
- Reduces visceral abdominal fat
- May improve triglycerides and body composition
- Injection site reactions
- Arthralgia
- Peripheral edema
- Glucose intolerance
- None listed
- 1.4 mg SC once daily
- 1.28 mg SC once daily
- High
- FDA-approved for HIV-associated lipodystrophy; supported by randomized clinical trials showing visceral fat reduction.
- Fda Approved
- Prescription required
- High
- FDA-approved for HIV-associated lipodystrophy; supported by randomized clinical trials showing visceral fat reduction.
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf
- https://pubmed.ncbi.nlm.nih.gov/20101189/
- Active malignancy
- Pregnancy
- Hypothalamic-pituitary axis disruption
- Hypersensitivity to tesamorelin or excipients
- None listed
- Fda Approved
- Prescription required
- Egrifta
- Egrifta SV
- Egrifta WR
- tesamorelin acetate
Educational reference only. Pepperz does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing recommendations.